Seres Therapeutics, Inc.

NASDAQ:MCRB

Biotechnology

Healthcare
$5.28 +1.70%

+$0.11 today

Market cap
$51.13M
Beta
0.11
P/E (TTM)
-1.3
EPS (TTM)
-$4.89
52W Low $5.31High $29.98

Volume 0.04M

Average 0.06M

MCRB Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

Seres Therapeutics, Inc.NASDAQ: MCRB

Accounts Payables · Q1 FY2026 · quarter ended Mar 2026

Accounts payables turns positive

Q1 FY2026 accounts payables was $656K, compared with -$1.97M a year earlier. Trailing-twelve-month accounts payables was $225K.

Context

  • Accounts payables amounted to 303.8% of revenue in FY2025.
  • Accounts payables increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly accounts payables holds near $656K or moves back toward the trailing-twelve-month quarterly average of $56.25K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$656K+13020.0% QoQ
Last fiscal yearDec 2025
-$2.4M-18.5% YoY
LTMMar 2026
$225K+103.5% YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+133.4%——
1 year-18.5%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2025
(2.4M) USD
Year-over-year change
+18.5%

Accounts Payables vs competitors

How MCRB compares with its peers on the latest reported figures

  • MCRB's LTM Mar 2026 accounts payables of $225K is the smallest of the 9 companies compared; the peer median is $1.5M.
  • Its year-over-year change of +103.5% is the 3rd highest of 8, against a peer median of +7.0%.
  • Accounts payables amounts to 19.6% of revenue for MCRB, versus a peer median of 12.8%.
MCRB Competitors Peer median
Accounts Payables for MCRB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
INOInovio Pharmaceuticals, Inc.LTM Mar 2026$4.12M -5.6%——
CGTXCognition Therapeutics, Inc.LTM Mar 2026$3.99M -200.8%——
SEERSeer, Inc.LTM Mar 2026$1.93M -198.4%—12.8%
IRDOpus Genetics, Inc.LTM Mar 2026$1.88M +559.7%—15.7%
SPROSpero Therapeutics, Inc.LTM Mar 2026$1.55M +19.0%+139.1%2.8%
ACTUActuate Therapeutics IncLTM Mar 2026$1.46M +7.0%——
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 2026$545K +126.9%——
HURATuHURA Biosciences, Inc.LTM Mar 2026$452.01K ———
MCRBSeres Therapeutics, Inc.LTM Mar 2026$225K +103.5%—19.6%
Peer median (excluding MCRB) $1.5M+7.0%+139.1%12.8%

Competitors are the stored peer set for MCRB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(65.58M)(250.16M)(113.72M)136K5.7M
Depreciation & Amortization5.95M6.63M6.24M5.47M4.13M
Deferred Income Tax00000
Stock-Based Compensation20.22M25.48M34.1M20.97M10.84M
Change in Working Capital41.53M(18.39M)(58.98M)(65.51M)(27.78M)
Accounts Receivables9.39M0(8.67M)(2.07M)1.55M
Inventory00(29.65M)(33.8M)0
Accounts Payables9.36M2.2M(11.58M)(2.94M)(2.4M)
Other Working Capital22.78M(20.59M)(9.08M)(26.71M)(26.93M)
Other Non-Cash Items4.57M7.62M15M(109.68M)8.23M
Operating Cash Flow6.69M(228.82M)(117.35M)(148.61M)1.12M
Capital Expenditures(9.57M)(9.82M)(7.98M)(380K)(252K)
Acquisitions (Net)0(92.25M)00210K
Purchases of Investments(95.97M)(48.22M)(4.43M)13.52M0
Sales of Investments169.63M140.47M22.98M142.67M0
Other Investing Activities092.25M0(13.52M)0
Investing Cash Flow64.09M82.43M10.58M142.29M(42K)
Debt Repayment(948K)25.7M50.52M(127.91M)0
Common Stock Issued2.13M101.17M18.16M23.53M13.9M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities2.13M2.74M3.03M14M0
Financing Cash Flow1.18M129.6M71.71M(90.37M)13.9M
Effect of Forex Changes(1K)(1K)2K(1K)0
Net Change in Cash71.95M(16.79M)(35.07M)(96.69M)14.97M
Free Cash Flow(2.88M)(238.64M)(125.33M)(148.99M)865K

Seres Therapeutics, Inc.

NASDAQ:MCRB

Intrinsic Alpha fair value

Locked

Current Price

$5.28

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.